Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Direxion Shares ETF Trust (CURE)

17 + Investors. Track Smart Money conviction in CURE. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↓ -3
Streak
3Q ▼
Buyers last Q
39%

Smart Money Signals — CURE

Based on 17 hedge funds · latest filing: 2026 Q1 · updated quarterly

📉

Selling streak — 3 quarters in a row

last 6Q
For 3 consecutive quarters, more hedge funds reduced or closed their CURE positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.
📊

High ownership — 74% of 3.0Y peak

74% of all-time peak
17 funds currently hold this stock — 74% of the 3.0-year high of 23 funds (reached 2024 Q4). Ownership is elevated but not yet at maximum concentration. Room to grow, but watch if the trend reverses.
📉

Outflows — 23% fewer funds vs a year ago

fund count last 6Q
5 fewer hedge funds hold CURE compared to a year ago (-23% decline). When institutions consistently reduce their exposure, it's worth exploring the underlying fundamental reasons driving them away.
🔴

Heavy selling pressure — only 39% buying

9 buying14 selling
Last quarter: 14 funds sold vs only 9 buyers. This is widespread institutional distribution — not a few funds rebalancing, but a broad exit. High conviction bearish signal.
➡️

Steady new buyers — ~2 new funds per quarter

new funds entering per quarter
Funds opening this position for the first time: 7 → 7 → 4 → 2. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.
🔒

59% of holders stayed for 2+ years

■ 59% conviction (2yr+) ■ 24% medium ■ 18% new
10 out of 17 hedge funds have held CURE for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
⚠️

Saturation — most institutions already know this story

7 → 7 → 7 → 4 → 2 new funds/Q
New funds entering each quarter: 7 → 7 → 4 → 2. Far fewer institutions are entering now vs. a year ago. When the pool of potential new buyers shrinks this fast, future price support from institutional inflows weakens significantly.
🏛️

Deep conviction — 73% of holders stayed 2+ years

■ 73% veterans ■ 9% 1-2yr ■ 18% new
Of 22 current holders: 16 (73%) have held for over 2 years without selling. These are not momentum buyers — they have lived through drawdowns and stayed. A large veteran base acts as a stabilizing force during selloffs.
🏆

Elite ownership — 82% AUM from top-100 funds

82% from top-100 AUM funds
6 of 17 holders are among the 100 largest funds by AUM, controlling 82% of total institutional value in CURE. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
2.7
out of 10
Low Exit Risk
Exit risk score 2.7/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — CURE

In 2026 Q1, 9 hedge funds were net buyers of CURE (2 opened a new position, 7 added to an existing one), while 14 reduced or exited (9 trimmed, 5 sold completely) — a 39% buyer ratio, indicating net institutional distribution. This extends a 3-quarter selling streak, suggesting sustained institutional caution. 82% of total institutional value in CURE is held by top-100 AUM funds, reflecting elite-tier ownership quality. Net fund flow last quarter: -3 funds (more exits than new entries). Total institutional holders: 17.

Hedge Fund Ownership: CURE

How many hedge funds hold CURE — quarterly history vs. share price
Quarterly hedge fund ownership of CURE vs. share price

Market Analysis: CURE

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: CURE

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Direxion Shares ETF Trust (CURE) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much CURE has moved relative to its sector benchmark (SPY) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 78d ago
CURE
+9.8%
SPY
+15.9%

CURE outperformed SPY by -6.1% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 33d ago
CURE
+15.4%
SPY
+2.0%

Since the filing became public, CURE outperformed SPY by +13.4% .

Interpretation: The stock has meaningfully outrun its sector. The trade has partially played out; entry is at a premium to the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

1 top-rated funds 0 high-conviction
Consensus
1.3
/ 10
breadth
×
Elite
0.0
/ 10
conviction
Hedge Fund Positioning: CURE
17 + Investors

Track Smart Money conviction in CURE. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 17 20 -15.0%
13F Shares 246K 310K -20.63%
Total Value $23M $35M -34.77%
New Positions 2 4 -2
Increased Positions 5 6 -1
Closed Positions 5 6 -1
Reduced Positions 8 8 -
Total Calls 4 3 33.33%
Total Puts 3 3 -
PUT/CALL Ratio 0.75 1.0 Neutral

Statistics: CURE

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

17 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in CURE. Verified SEC 13F-HR filings.

QUARTER:
Top 22 CURE holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Gts Securities LLC 0.04% 11,929 $1.1M
2 Traynor Capital Management, Inc. 0.03% 5,212 $452K
3 Onyx Bridge Wealth Group LLC 0.02% 2,485 $228K
4 SBI Securities Co., Ltd. 0.02% 6,355 $582K
5 Pinnacle Wealth Planning Services, Inc. 0.00% 455 $42K
6 Summit Financial, LLC 0.00% 2,848 $261K
7 Belvedere Trading LLC 0.00% 10,900 $998K
8 Tower Research Capital LLC (TRC) 0.00% 438 $40K
9 Citadel Advisors LLC 0.00% 52,100 $4.8M
10 Susquehanna International Group, LLP 0.00% 67,200 $6.2M
11 Osaic Holdings, INC. 0.00% 3,616 $331K
12 Susquehanna International Group, LLP 0.00% 27,900 $2.6M
13 Citadel Advisors LLC 0.00% 17,600 $1.6M
14 Farther Finance Advisors, LLC 0.00% 262 $25K
15 Jane Street Group, LLC 0.00% 12,800 $1.2M
16 Susquehanna International Group, LLP 0.00% 14,032 $1.3M
17 Jane Street Group, LLC 0.00% 6,600 $604K
18 Jane Street Group, LLC 0.00% 3,351 $307K
19 Group One Trading LLC 0.00% 46 $4K
20 Simplex Trading, LLC 0.00% 125 $11K
21 Morgan Stanley 0.00% 1 —
22 Wells Fargo & Company/Mn 0.00% 1 —
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Direxion Shares ETF Trust (CURE)

What does the Smart Money Trend signal show for CURE?

Selling streak — 3 quarters in a row: For 3 consecutive quarters, more hedge funds reduced or closed their CURE positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for CURE?

Heavy selling pressure — only 39% buying: Last quarter: 14 funds sold vs only 9 buyers. This is widespread institutional distribution — not a few funds rebalancing, but a broad exit. High conviction bearish signal.

What is the fund quality score for CURE holders?

Elite ownership — 82% AUM from top-100 funds: 6 of 17 holders are among the 100 largest funds by AUM, controlling 82% of total institutional value in CURE. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held CURE?

59% of holders stayed for 2+ years: 10 out of 17 hedge funds have held CURE for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Direxion Shares ETF Trust (CURE) following the 2026 Q1 hedge fund 13F filings?

As of today, CURE has moved +15.4% since the 2026 Q1 13F filing date (May 15, 2026), compared to +2.0% for the SPY sector ETF — an outperformance of +13.4%. Since the quarter end (March 31, 2026), CURE has gained +9.8% vs +15.9% for SPY. The stock has meaningfully outrun its sector. The trade has partially played out; entry is at a premium to the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →